LifeMD Posts Strong 2025 Growth, Eyes GLP-1 Expansion
Event summary
- LifeMD reported 25% full-year revenue growth to $194.1M in 2025, with adjusted EBITDA rising 309% to $15.3M.
- Fourth-quarter revenue increased 4% to $46.9M, while adjusted EBITDA surged 348% to $4.8M.
- Launched oral Wegovy post-year-end, with over 80% of new weight management patients initiating branded therapy.
- Exited 2025 with $36.8M in cash and no debt, positioning for accelerated growth investments.
- Active telehealth subscribers grew 16% to 323,000, with benefits infrastructure expected to cover 220M Americans by Q2 2026.
The big picture
LifeMD's strong financial performance in 2025 underscores the growing demand for virtual primary care services, particularly in weight management and women's health. The company's strategic focus on expanding its GLP-1 therapy offerings and scaling its benefits infrastructure positions it to capitalize on the broader shift towards telehealth solutions. With a robust balance sheet and a clear path to profitability, LifeMD is well-positioned to lead in this transformative market.
What we're watching
- GLP-1 Market Penetration
- How LifeMD will leverage the launch of oral Wegovy to capture a larger share of the GLP-1 therapy market, where only a fraction of eligible patients are currently treated.
- Execution Risk
- Whether LifeMD can sustain its aggressive patient acquisition strategy while maintaining profitability, especially as it invests heavily in expanding its platform.
- Regulatory Dynamics
- The pace at which Medicare coverage for GLP-1 medications and other regulatory developments will impact LifeMD's growth trajectory.
Related topics